The main reason for not sharing DNA for drug research is the fear it could be used without knowledge for corporate gain
News
Private clinic launches UK’s first MRIdian radiotherapy machine
NHS patients will be able to access the treatment via clinical trials
SMC green light for rare blood cancer treatment
NHS funding was backed for four medicines
RCEM’s winter data reveals much worse picture of A&E waits
“We are clearly in the worst state we’ve ever been in as we enter the true winter season”, says College president Dr Katherine Henderson.
Healx, Boehringer link for rare neurological disease therapy
The project will utilise Healx’ AI-based drug discovery platform
Sanofi bulks up cancer offering with Synthorx buy
The French drugmaker is spending around $2.5 billion on the deal
AZ’ Calquence boosts PFS in CLL patients
The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Survey reveals ‘critical deficiencies’ in NHS record-keeping
Policymakers must identify fragmented systems and promote better data sharing, study authours say
CAR-T therapies shine at ASH
Janssen’s JNJ-4528 and BMS’ liso-cel show 100% response rates
Novartis, Amazon ink deal for ‘smart’ manufacturing
The online retail giant’s honed data abilities will help Novartis produce more personalised therapies.
Astellas, Audentes pen $3bn gene therapy deal
Genetic regulation is set to become a fifth primary focus for the Japanese drugmaker, on top of its already existing business lines.
ViiV Healthcare submits HIV drug fostemsavir in the US
The treatment could offer a new option for patients unable to reach viral supression
PharmaTimes unveils winners of MSEA 2019
This year’s competition welcomed a fantastic spread of companies as well as a higher number of entrants
INTCR 2020 Executive Steering Group Chair shares insight into this ever-growing competition
Flying the flag for clinical research for over 20 years, this competition continues to grow and develop year after year.
Late-stage Ibsrela success for Ardelyx
If approved, the drug will be the only non-binder treatment for the control of serum phosphorus in patients with CKD on dialysis.
